NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$14.82 +0.06 (+0.41 %)
(As of 08/15/2018 02:47 AM ET)
Previous Close$14.76
Today's Range$14.72 - $15.04
52-Week Range$2.69 - $15.80
Volume304,500 shs
Average Volume515,707 shs
Market Capitalization$773.07 million
P/E Ratio-4.05
Dividend YieldN/A
Beta2.33
Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097

Debt

Debt-to-Equity Ratio0.14
Current Ratio5.40
Quick Ratio5.40

Price-To-Earnings

Trailing P/E Ratio-4.05
Forward P/E Ratio-10.74
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.28 million
Price / Sales344.18
Cash FlowN/A
Price / CashN/A
Book Value$1.96 per share
Price / Book7.56

Profitability

EPS (Most Recent Fiscal Year)($3.66)
Net Income$-60,040,000.00
Net Margins-1,642.81%
Return on Equity-97.39%
Return on Assets-61.25%

Miscellaneous

Employees44
Outstanding Shares52,950,000
Market Cap$773.07 million

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) posted its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.26. The biopharmaceutical company earned $1.55 million during the quarter, compared to the consensus estimate of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. View Dicerna Pharmaceuticals' Earnings History.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

What price target have analysts set for DRNA?

7 analysts have issued 1 year target prices for Dicerna Pharmaceuticals' stock. Their forecasts range from $10.00 to $20.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $14.75 in the next twelve months. This suggests that the stock has a possible downside of 0.5%. View Analyst Price Targets for Dicerna Pharmaceuticals.

What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Who are some of Dicerna Pharmaceuticals' key competitors?

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas M. Fambrough III, Co-Founder, Chief Exec. Officer, Pres and Director (Age 49)
  • Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 53)
  • Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 65)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 71)

Has Dicerna Pharmaceuticals been receiving favorable news coverage?

Press coverage about DRNA stock has trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a news and rumor sentiment score of 0.13 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Dicerna Pharmaceuticals.

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include RTW Investments LP (9.53%), BlackRock Inc. (4.94%), FMR LLC (2.73%), Emerald Advisers Inc. PA (1.14%), Emerald Mutual Fund Advisers Trust (1.00%) and Bank of New York Mellon Corp (0.30%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

Which major investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC and Spark Investment Management LLC. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Which major investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Bank of New York Mellon Corp, DAFNA Capital Management LLC, Schwab Charles Investment Management Inc., Bank of Montreal Can and Swiss National Bank. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $14.82.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $773.07 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.